1. Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review.
- Author
-
Laydner, Humberto K., Oliveira, Paulo, Oliveira, Carlos Roberto A., Makarawo, Tafadzwa P., Andrade, Weslley S., Tannus, Matheus, and Araújo, José Luciano R.
- Subjects
PHOSPHODIESTERASE inhibitors ,DRUG efficacy ,SYMPTOMS ,BENIGN prostatic hyperplasia ,HEALTH outcome assessment ,RANDOMIZED controlled trials ,HETEROGENEITY ,META-analysis - Abstract
OBJECTIVE To review the evidence in support of the effectiveness of phosphodiesterase 5 inhibitors in lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). METHODS Relevant studies were identified by performing a literature search using MEDLINE® and The Cochrane Library®. The criteria used during the search included randomized, placebo-controlled trials of treatment for LUTS secondary to BPH using the International Prostate Symptom Score as an outcome measure. RESULTS Four trials that included a total of 1928 patients met the inclusion criteria. All four studies showed a statistically significant difference in the International Prostate Symptom Score, quality of life and erectile function in favour of phosphodiesterase 5 inhibitors. No study showed a statistically significant improvement of the maximum urinary flow. Meta-analysis of the results was not possible because of heterogeneity across the studies. CONCLUSIONS Phosphodiesterase 5 inhibitors used in the clinical setting can significantly improve LUTS secondary to BPH, erectile function and quality of life. Maximum urinary flow improvement is not statistically significant. Future research should focus on pathophysiological principles and cost analysis. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF